Caribou Biosciences, Inc. (CRBU)
CRBU moved a median of -0.67% 30 minutes after news, and -0.72% by the close. How CRBU actually reacts to news — the realized, point-in-time move the market made, measured across 686 labeled events over the last three years with zero look-ahead.
CRBU’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.38% | 37% | 686 |
| 30-min | -0.67% | 37% | 686 |
| 60-min | -0.67% | 38% | 686 |
| to close | -0.72% | 38% | 683 |
| Middle 50% of CRBU reactions | -2.29% to +1.12% |
|---|---|
| Median reaction (30-min) | -0.67% |
| Measured reactions | 686 |
Half of all Caribou Biosciences, Inc. news events land between -2.29% and +1.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CRBU moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CRBU's baseline. Nothing else.
Recent CRBU events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Caribou Biosciences to Evaluate Strategic Alternatives | Press release | GlobeNewswire | -3.19% | -0.42% | |
| Form 8-K Caribou Biosciences, For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | -3.19% | -0.42% | |
| Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.93% | -1.86% | |
| Form 10-Q Caribou Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.93% | -1.86% | |
| Form 8-K Caribou Biosciences, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.93% | -1.86% | |
| Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Press release | GlobeNewswire | -0.29% | +4.12% | |
| Form 8-K Caribou Biosciences, For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | +0.61% | |
| Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting | Press release | GlobeNewswire | -3.33% | -7.78% | |
| Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 | Press release | GlobeNewswire | -3.33% | -7.78% | |
| Form 8-K Caribou Biosciences, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | -7.78% | |
| Form DEFA14A Caribou Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -1.53% | -6.12% | |
| Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.43% | +0.43% | |
| Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference | Press release | GlobeNewswire | -0.47% | +0.47% | |
| Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting | Press release | GlobeNewswire | -1.00% | +0.49% | |
| Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.26% | +2.10% | |
| Form 10-Q Caribou Biosciences, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.26% | +2.10% | |
| Form 8-K Caribou Biosciences, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +2.10% | |
| Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference | Press release | GlobeNewswire | -1.27% | -1.01% | |
| Form DEFR14A Caribou Biosciences, | SEC filing · Form DEFR14A | SEC EDGAR | +3.20% | +3.24% | |
| Form ARS Caribou Biosciences, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.37% | -2.74% | |
| Form DEF 14A Caribou Biosciences, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -1.37% | -2.74% | |
| Form DEFA14A Caribou Biosciences, | SEC filing · Form DEFA14A | SEC EDGAR | -1.37% | -2.74% | |
| Form PRE 14A Caribou Biosciences, For: Dec 31 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +2.09% | |
| Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy | Press release | GlobeNewswire | +9.44% | +5.56% | |
| Form 8-K Caribou Biosciences, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +9.44% | +5.56% | |
| Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.68% | +7.69% | |
| Form 10-K Caribou Biosciences, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.68% | +7.69% | |
| Form 8-K Caribou Biosciences, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +7.69% | |
| Form S-8 Caribou Biosciences, | SEC filing · Form S-8 | SEC EDGAR | +1.68% | +7.69% | |
| Caribou Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.30% | +2.60% | |
| Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® | Press release | GlobeNewswire | -1.26% | +1.89% | |
| Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 | Press release | GlobeNewswire | +0.00% | -1.12% | |
| Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -7.39% | — | |
| Form 10-Q Caribou Biosciences, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.39% | — | |
| Form 8-K Caribou Biosciences, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -7.39% | — | |
| Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies | Press release | GlobeNewswire | -7.52% | -28.32% | |
| Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma | Press release | GlobeNewswire | -7.52% | -28.32% | |
| Caribou Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.46% | -9.58% | |
| Form 8-K Caribou Biosciences, For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -7.52% | -28.32% | |
| Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma | Press release | GlobeNewswire | -7.52% | -28.32% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.18% | -6.67% | |
| Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.65% | +1.74% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.45% | +4.02% | |
| Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | -1.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.45% | +12.21% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.28% | -0.28% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | -0.54% | |
| Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference | Press release | GlobeNewswire | +1.05% | +5.26% | |
| Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.04% | +13.37% | |
| Form 10-Q Caribou Biosciences, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.04% | +13.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CRBU section they belong to.
Where else CRBU is measured.
CRBU earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Caribou Biosciences, Inc.'s median reaction calculated?
Every labeled CRBU news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 686 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of CRBU's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CRBU's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.